learn
underli demand continu expans high-growth
biolog acceler organ growth
guidanc align long-term target rais
estim increas pt reiter ow
strong finish improv visibl catal result
benefit combin recoveri softgel paragon acquisit
complet lower tax look ahead fiscal guidanc
impli organ growth rate core busi complement
growth acquisit track achiev long-term goal
organ growth rate outlook support continu expans biolog
dissip softgel headwind notabl recent agreement
sanofi underscor increas level interest larg pharma client
put take ebitda profil ebitda guidanc million
impli margin expans bp fiscal addit bp
expans target fiscal benefit higher-margin paragon
busi versu core biolog margin acceler growth
higher-margin oral drug deliveri segment versu corpor
margin line fiscal trend manag anticip sequenti
ramp ebitda split
biolog expect underli trend remain strong
exclud paragon core biolog segment organ revenu grew y/i
ebitda declin y/i quarter neg impact custom
contract loss drug substanc busi would continu headwind
next quarter exclud contract loss manag reiter
expect double-digit organ growth busi driven continu
invest faster grow market
updat model estim reflect guidanc revis top-line
forecast revenu million million y/i line
high end guidanc rang million million lower
revenu reflect contract loss headwind biolog specialti drug
 distribut unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
deliveri segment rais ebitda estim million
million account margin expans ep unchang
rais price target base base-cas dcf
analysi updat target impli ev/ebitda multipl within
high end rang histor ntm ev/ebitda
multipl line averag ev/ebitda multipl
cmo/cro peer group iqvia charl river
cambrex strong demand outlook improv growth profil
margin expans opportun support premium valuat risk reward
snapshot detail
base case dcf includ termin growth wacc
ev/ebitda bull case ebitda
ev/ebitda bull case ebitda
grow lt target top-line organ growth
normal driven out-performance biolog
trend mid-singl digit softgel growth improv site util
revenu strength lead annual organ ebitda margin expans bp
y/i near-term
ev/ebitda base case ebitda
ev/ebitda base case ebitda
organ top-line growth medium term modest
ebitda margin expans top-line organ growth normal
biolog specialti drug deliveri
contribut greatest dollar growth adj ebitda margin expand
y/i near-term paragon acquisit busi mix shift
improv economi scale
ev/ebitda bear case ebitda
ev/ebitda bear case ebitda
grow lt revenu target ebitda margin see limit
expans top-line growth normal
weak softgel trend growth paragon
biolog fail materi organ adj ebitda margin contract
normal y/i expans
largest public pure play
pharmaceut compani
compani follow molecul
manufactur formul clinic
stage commerci product
creat high level client sticki
portfolio servic align
pipelin increasingli complex molecul
reli advanc deliveri technolog
post-integr paragon cook
pharmica biolog account
revenu mix posit doubl
strateg partnership larg pharma
quarterli result focu backlog
risk achiev price
manag fail capit organ
 growth opportun
continu pressur earn
facil shutdown due regulatori issu
unforese event
margin contract driven biopharma
new drug launch fail reach potenti
and/or project delay cancel
ow pt price target base base case dcf analysi
risk valuat includ manag fail capit organ growth
 opportun continu pressur earn fx headwind
unanticip facil shutdown due weather regulatori issu
unforese event new drug launch fail reach potenti and/or project
delay cancel
inform opinion research prepar co llc and/or and/or morgan
stanley mexico de bolsa de and/or canada limit use disclosur section includ morgan
stanley co llc mexico de bolsa de canada limit affili
necessari
import disclosur stock price chart equiti rate histori regard compani subject report pleas see morgan
stanley research disclosur websit www morganstanley com/researchdisclosur contact invest repres
research broadway attent research manag new york ny usa
valuat methodolog risk associ recommend rate price target referenc research report pleas contact client
support follow us/canada hong kong latin america london
singapor sydney tokyo altern may contact invest repres morgan
stanley research broadway attent research manag new york ny usa
follow analyst herebi certifi view compani secur discuss report accur express
receiv receiv direct indirect compens exchang express specif recommend view report ricki
unless otherwis state individu list cover page report research analyst
morgan stanley research publish accord conflict manag polici avail
www morganstanley com/institutional/research/conflictpolici portugues version polici found www morganstanley com br
import us regulatori disclosur subject compani
